Literature DB >> 29708234

[Rare diseases: laying out some challenges].

.   

Abstract

Entities:  

Year:  2017        PMID： 29708234      PMCID： PMC5920522     

Source DB:  PubMed          Journal:  Cambios Rev Med        ISSN： 1390-5511


× No keyword cloud information.
  6 in total

Review 1.  A comparative study of European rare disease and orphan drug markets.

Authors:  Alain Denis; Lut Mergaert; Christel Fostier; Irina Cleemput; Steven Simoens
Journal:  Health Policy       Date:  2010-06-17       Impact factor: 2.980

2.  Open letter to prime minister David Cameron and health secretary Andrew Lansley.

Authors:  David J Nicholl; David Hilton-Jones; Jacqueline Palace; Sam Richmond; Sarah Finlayson; John Winer; Andrew Weir; Paul Maddison; Nick Fletcher; Jon Sussman; Nick Silver; John Nixon; Dimitri Kullmann; Nick Embleton; David Beeson; Maria Elena Farrugia; Marguerite Hill; Chris McDermott; Gareth Llewelyn; James Leonard; Michael Morris
Journal:  BMJ       Date:  2010-11-16

3.  What makes an orphan drug?

Authors:  Nigel Hawkes; Deborah Cohen
Journal:  BMJ       Date:  2010-11-16

4.  Which orphans will find a home? The rule of rescue in resource allocation for rare diseases.

Authors:  Emily A Largent; Steven D Pearson
Journal:  Hastings Cent Rep       Date:  2012 Jan-Feb       Impact factor: 2.683

5.  Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I.

Authors:  Raquel Boy; Ida V D Schwartz; Bárbara C Krug; Luiz C Santana-da-Silva; Carlos E Steiner; Angelina X Acosta; Erlane M Ribeiro; Marcial F Galera; Paulo G C Leivas; Marlene Braz
Journal:  J Med Ethics       Date:  2011-01-25       Impact factor: 2.903

6.  How did uncommon disorders become 'rare diseases'? History of a boundary object.

Authors:  Caroline Huyard
Journal:  Sociol Health Illn       Date:  2009-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.